Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for magnesium
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) 7908076 1994 04 28 1994 04 28 2015 06 16 0140-6736 343 8901 1994 Apr 02 Lancet (London, England) Lancet Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) 816-9 The second Leicester Intravenous Magnesium (...) Intervention Trial (LIMIT-2) examined the effect of an intravenous regimen of magnesium sulphate in 2316 patients with suspected acute myocardial infarction. Treatment, according to a double-blind randomised protocol, was started with a loading injection, before any thrombolytic therapy, and continued with a maintenance infusion for a further 24 h. Cause-specific mortality of randomised patients has now been examined over 1.0-5.5 (mean 2.7) years of follow-up. Mortality rate from ischaemic
Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. 7920126 1994 10 27 1994 10 27 2013 11 21 0959-8138 309 6952 1994 Aug 13 BMJ (Clinical research ed.) BMJ Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. 436-40 To examine the effect of a reduced sodium and increased potassium and magnesium intake on blood (...) pressure. Randomised double blind placebo controlled trial. General population of a suburb of Rotterdam. 100 men and women between 55 and 75 years of age with untreated mild to moderate hypertension. During 24 weeks the intervention group received a mineral salt (sodium: potassium: magnesium 8:6:1) and foods prepared with the mineral salt. Controls received common salt and foods. Change in blood pressure. Complete follow up was achieved for 97 of the 100 randomised subjects. Systolic blood pressure (mean
Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. 8401013 1993 11 09 1993 11 09 2013 11 21 0959-8138 307 6904 1993 Sep 04 BMJ (Clinical research ed.) BMJ Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. 585-7 To investigate the effect of long term oral magnesium treatment on incidence of cardiac events among survivors of an acute myocardial infarction. Double blind (...) , placebo controlled parallel study in which patients were randomised to treatment or placebo. Two coronary care units and corresponding outpatient clinics. 468 survivors of an acute myocardial infarction (289 men and 178 women) aged 31-92. One tablet of 15 mmol magnesium hydroxide or placebo daily for one year. Incidences of reinfarction, sudden death, and coronary artery bypass grafting in one year. There was no significant difference between treatment and placebo groups in the incidence of each
Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. 1404796 1992 11 25 1992 11 25 2016 10 17 0098-7484 268 17 1992 Nov 04 JAMA JAMA Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. 2395-402 To determine whether magnesium administration is effective in reducing postoperative morbidity and mortality after cardiac surgery. Randomized, double-blind, placebo (...) -controlled trial. A tertiary acute-care 500-bed university teaching hospital. Over a 6-month period, 100 patients electively scheduled for cardiac surgery involving cardiopulmonary bypass were studied. Fifty patients were randomized to receive an intravenous infusion of magnesium chloride, 2 g, and 50 patients received placebo intraoperatively after the termination of cardiopulmonary bypass. Magnesium-treated patients had a significantly decreased frequency (P < .04) of postoperative ventricular
Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) 1351547 1992 07 21 1992 07 21 2015 06 16 0140-6736 339 8809 1992 Jun 27 Lancet (London, England) Lancet Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) 1553-8 The cardiovascular actions of the magnesium ion at pharmacological (...) concentrations include coronary and systemic vasodilatation, platelet inhibition, and antiarrhythmic effects. Magnesium has also been reported to protect myocardial tissue in experimental models of ischaemia and reperfusion. Several small clinical trials in suspected acute myocardial infarction have suggested that early mortality can be reduced by intravenous infusion of magnesium salts in the acute phase, but none has been of sufficient size to be conclusive. We therefore conducted a randomised, double
Red blood cell magnesium and chronic fatigue syndrome. 1672392 1991 04 25 1991 04 25 2015 06 16 0140-6736 337 8744 1991 Mar 30 Lancet (London, England) Lancet Red blood cell magnesium and chronic fatigue syndrome. 757-60 The hypotheses that patients with chronic fatigue syndrome (CFS) have low red blood cell magnesium and that magnesium treatment would improve the wellbeing of such patients were tested in a case-control study and a randomised, double-blind, placebo-controlled trial (...) , respectively. In the case-control study, 20 patients with CFS had lower red cell magnesium concentrations than did 20 healthy control subjects matched for age, sex, and social class (difference 0.1 mmol/l, 95% confidence interval [CI] 0.05 to 0.15). In the clinical trial, 32 patients with CFS were randomly allocated either to intramuscular magnesium sulphate every week for 6 weeks (15 patients) or to placebo (17). Patients treated with magnesium claimed to have improved energy levels, better emotional
Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. 2207419 1990 11 06 1990 11 06 2013 11 21 0959-8138 301 6751 1990 Sep 15 BMJ (Clinical research ed.) BMJ Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. 521-3 To evaluate the antihypertensive activity of potassium given alone or in combination with magnesium in patients with mild hypertension. A double blind (...) , randomised, placebo controlled, crossover trial of 32 weeks' duration. Cardiology outpatient department, Sassoon General Hospitals, Pune, India. 37 Adults with mild hypertension (diastolic blood pressure less than 110 mm Hg). Patients received either placebo or potassium 60 mmol/day alone or in combination with magnesium 20 mmol/day in a crossover design. No other drug treatment was allowed. Blood pressure and heart rate assessed at weekly intervals and biochemical parameters at monthly intervals
Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. 2761061 1989 09 19 1989 09 19 2016 10 17 0098-7484 262 9 1989 Sep 01 JAMA JAMA Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. 1210-3 Conventional nebulized beta-agonist therapy has met with disappointing results in an increasing number of moderate to severe asthmatics who may be characterized as "poor responders." Thirty-eight patients suffering from acute (...) exacerbations of moderate to severe asthma were treated in an emergency department with an intravenous infusion of saline placebo or 1.2 g of magnesium sulfate after conventional beta-agonist therapy failed to produce significant improvement in peak expiratory flow rate. Nineteen patients were randomized into each of two groups in a placebo-controlled, double-blind clinical trial. The treatment group demonstrated an increase in peak expiratory flow rate from 225 to 297 L/min as compared with 208 to 216 L
Intravenous magnesium in acute myocardial infarction. 2868254 1986 03 12 1986 03 12 2015 06 16 0140-6736 1 8475 1986 Feb 01 Lancet (London, England) Lancet Intravenous magnesium in acute myocardial infarction. 234-6 In a double-blind, placebo-controlled study, 273 patients with suspected acute myocardial infarction (AMI) were randomised to receive either magnesium intravenously or placebo immediately on admission to hospital. Of 130 patients with proven AMI 56 received magnesium and 74 received (...) placebo. During the first 4 weeks after treatment mortality was 7% in the magnesium group and 19% in the placebo group. In the magnesium group 21% of patients had arrhythmias that needed treatment, compared with 47% in the placebo group. No adverse effects of intravenous magnesium were observed. Rasmussen H S HS McNair P P Norregard P P Backer V V Lindeneg O O Balslev S S eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Isoenzymes 02F3473H9O Magnesium
Magnesium therapy in neonatal tetany. 64807 1977 03 31 1977 03 31 2015 06 16 0140-6736 1 8006 1977 Feb 05 Lancet (London, England) Lancet Magnesium therapy in neonatal tetany. 283-4 104 infants with symptomatic hypocalcaemia were randomly allocated to treatment with calcium gluconate, phenobarbitone, or magnesium sulphate. Infants treated with magnesium sulphate had higher plasma-calcium concentrations after 48 hours' treatment and fewer convulsions during and after the treatment period (...) . Magnesium sulphate is recommended as the treatment of choice in symptomatic neonatal tetany whether or not there is hypomagnesaemia. Turner T L TL Cockburn F F Forfar J O JO eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 27YLU75U4W Phosphorus 7487-88-9 Magnesium Sulfate I38ZP9992A Magnesium SY7Q814VUP Calcium YQE403BP4D Phenobarbital AIM IM Administration, Oral Calcium administration & dosage blood therapeutic use Drug Evaluation Humans